Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say